Ji Wei, Wang Lü-hua, Ou Guang-fei, Liang Jun, Feng Qin-fu, Xiao Ze-fen, Chen Dong-fu, Lü Ji-ma, Zhou Zong-mei, Zhang Hong-xing, Yin Wei-bo
Department of Radiation Oncology, Cancer Institute (Hospital), Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2008 Oct;30(10):783-6.
To investigate the association between survival and postoperative three-dimensional conformal radiotherapy (3DCRT) in patients with resected non-small cell lung cancer (NSCLC).
Eighty-four patients were treated with surgery and postoperative 3DCRT for NSCLC. Sixty-five (77.4%) patients received lobectomy, and 19 (22.6%) received pneumonectomy. Fifty-four (64.3%) patients achieved R0 resection and 30 cases (35.8%) received R1/R2 resection. Fifty-two patients were of stage IIIA and 24 patients were of stage IIIB. Photon energy of 6 MV was used for all the patients. The median 3DCRT dose was 60 Gy (40 - 70 Gy) with a fraction size of 2 Gy. Thirty-seven patients received median 3 cycles of adjuvant chemotherapy. The median follow-up was 35.5 months for survivors.
The overall 3-year survival rate was 58.6%, and the 4-year overall survival rate was 43.9%. Of the 43 patients who had treatment failure, only 8 (9.9%) patients showed intrathoracic recurrence, but 38 (46.9%) patients had distant metastasis. The univariate analysis for all patients showed that sex, age, weight loss, tumor size, pathology and stage were not correlated with prognosis. R1/R2 resection was associated with a significantly worse survival. Toxicities were acceptable, with 9 (11.1%) patients appeared higher than NCI CTC grade 2 radiation pneumonitis.
In a population-based cohort, postoperative 3DCRT for NSCLC provides a good prognosis, and the radiation-related pneumonitis is acceptable.
探讨手术切除的非小细胞肺癌(NSCLC)患者的生存情况与术后三维适形放疗(3DCRT)之间的关联。
84例NSCLC患者接受了手术及术后3DCRT治疗。65例(77.4%)患者行肺叶切除术,19例(22.6%)患者行全肺切除术。54例(64.3%)患者实现R0切除,30例(35.8%)患者接受R1/R2切除。52例患者为ⅢA期,24例患者为ⅢB期。所有患者均使用6 MV光子能量。3DCRT中位剂量为60 Gy(40 - 70 Gy),分割剂量为2 Gy。37例患者接受中位3周期辅助化疗。幸存者的中位随访时间为35.5个月。
总体3年生存率为58.6%,4年总生存率为43.9%。在43例治疗失败的患者中,仅8例(9.9%)患者出现胸内复发,但38例(46.9%)患者发生远处转移。对所有患者的单因素分析显示,性别、年龄、体重减轻、肿瘤大小、病理及分期与预后均无相关性。R1/R2切除与显著较差的生存率相关。毒性反应可接受,9例(11.1%)患者出现高于美国国立癌症研究所(NCI)常见毒性标准(CTC)2级的放射性肺炎。
在基于人群的队列研究中,NSCLC术后3DCRT预后良好,且放射性肺炎可接受。